Safety and E cacy of Neostigmine Against Residual Neuromuscular Blockade in Pediatric Patients During Recovery From General Anesthesia: A Retrospective Cohort Study

[1]  T. Clutton-Brock,et al.  Association of Anaesthetists of Great Britain and Ireland , 1984 .

[2]  A. Dahan,et al.  Safety of sugammadex for reversal of neuromuscular block , 2019, Expert opinion on drug safety.

[3]  M. Fischler,et al.  Efficacy of Sugammadex in Preventing Skin Test Reaction in a Patient With Confirmed Rocuronium Anaphylaxis: A Case Report. , 2019, A&A practice.

[4]  A. Tsiotou,et al.  A multicenter survey on the use of neuromuscular blockade in Greece. Does the real-world clinical practice indicate the necessity of guidelines? , 2019, Journal of anaesthesiology, clinical pharmacology.

[5]  J. Klučka,et al.  Residual neuromuscular block in paediatric anaesthesia. , 2019, British journal of anaesthesia.

[6]  Jie Luo,et al.  Reevaluation and update on efficacy and safety of neostigmine for reversal of neuromuscular blockade , 2018, Therapeutics and clinical risk management.

[7]  H. Yasunaga,et al.  Association between sugammadex and anaphylaxis in pediatric patients: A nested case‐control study using a national inpatient database , 2018, Paediatric anaesthesia.

[8]  T. Loftsson,et al.  Solubility of Cyclodextrins and Drug/Cyclodextrin Complexes , 2018, Molecules.

[9]  H. Arkes,et al.  Consensus Statement on Perioperative Use of Neuromuscular Monitoring , 2017, Anesthesia and analgesia.

[10]  H. Sunaga,et al.  Incidence of Anaphylaxis Associated With Sugammadex , 2017, Anesthesia and analgesia.

[11]  G. Murphy,et al.  Neostigmine Administration after Spontaneous Recovery to a Train-of-Four Ratio of 0.9 to 1.0: A Randomized Controlled Trial of the Effect on Neuromuscular and Clinical Recovery , 2018, Anesthesiology.

[12]  J. Hunter,et al.  Reversal of residual neuromuscular block: complications associated with perioperative management of muscle relaxation , 2017, British journal of anaesthesia.

[13]  S. Brull,et al.  Current Status of Neuromuscular Reversal and Monitoring: Challenges and Opportunities , 2017, Anesthesiology.

[14]  M. R. Gätke,et al.  Objective neuromuscular monitoring of neuromuscular blockade in Denmark: an online‐based survey of current practice , 2017, Acta anaesthesiologica Scandinavica.

[15]  J. Richman,et al.  Intermediate-Acting Nondepolarizing Neuromuscular Blocking Agents and Risk of Postoperative 30-Day Morbidity and Mortality, and Long-term Survival , 2017, Anesthesia and analgesia.

[16]  A. Arıboğan,et al.  Anesthesia management and sugammadex experience in a neonate for Galen vein aneurysm. , 2016, Journal of clinical anesthesia.

[17]  J. Mccormack,et al.  The presumed central nervous system effects of rocuronium in a neonate and its reversal with sugammadex , 2016, Paediatric anaesthesia.

[18]  M. H. Nathanson,et al.  Recommendations for standards of monitoring during anaesthesia and recovery 2015 : Association of Anaesthetists of Great Britain and Ireland[Link] , 2015, Anaesthesia.

[19]  T. Takazawa,et al.  Sugammadex and rocuronium-induced anaphylaxis , 2015, Journal of Anesthesia.

[20]  T. Kurth,et al.  Dose-dependent Association between Intermediate-acting Neuromuscular-blocking Agents and Postoperative Respiratory Complications , 2015, Anesthesiology.

[21]  B. Hindman,et al.  The Implementation of Quantitative Electromyographic Neuromuscular Monitoring in an Academic Anesthesia Department , 2014, Anesthesia and analgesia.

[22]  S. Phillips,et al.  A Survey of the Management of Neuromuscular Blockade Monitoring in Australia and New Zealand , 2013, Anaesthesia and intensive care.

[23]  Jesse M. Ehrenfeld,et al.  Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study , 2012, BMJ : British Medical Journal.

[24]  T. Yatabe,et al.  Successful management of rocuronium-induced anaphylactic reactions with sugammadex: a case report. , 2012, Journal of clinical anesthesia.

[25]  L. Green,et al.  Sugammadex in the management of rocuronium-induced anaphylaxis. , 2011, British journal of anaesthesia.

[26]  M. Eikermann,et al.  Neostigmine/Glycopyrrolate Administered after Recovery from Neuromuscular Block Increases Upper Airway Collapsibility by Decreasing Genioglossus Muscle Activity in Response to Negative Pharyngeal Pressure , 2010, Anesthesiology.

[27]  D. Chambers,et al.  Sugammadex for reversal of neuromuscular block after rapid sequence intubation: a systematic review and economic assessment. , 2010, British journal of anaesthesia.

[28]  J. Viby-Mogensen,et al.  Evidence-based management of neuromuscular block. , 2010, Anesthesia and analgesia.

[29]  S. Brull,et al.  A Survey of Current Management of Neuromuscular Block in the United States and Europe , 2010, Anesthesia and analgesia.

[30]  O. Meretoja.  Neuromuscular block and current treatment strategies for its reversal in children , 2010, Paediatric anaesthesia.

[31]  Ronald D. Miller,et al.  Monitoring and pharmacologic reversal of a nondepolarizing neuromuscular blockade should be routine. , 2010, Anesthesia and analgesia.

[32]  Glenn S. Murphy,et al.  Residual Neuromuscular Block: Lessons Unlearned. Part I Definitions, Incidence, and Adverse Physiologic Effects of Residual Neuromuscular Block , 2010, Anesthesia and analgesia.

[33]  Martin H. Dauber,et al.  Miller’s Anesthesia , 2010 .

[34]  G. Della Rocca,et al.  Knowledge of residual curarization: an Italian survey , 2010, Acta anaesthesiologica Scandinavica.

[35]  M. Eikermann,et al.  Antagonism of non‐depolarising neuromuscular block: current practice , 2009, Anaesthesia.

[36]  B. Plaud,et al.  Reversal of Rocuronium-induced Neuromuscular Blockade with Sugammadex in Pediatric and Adult Surgical Patients , 2009, Anesthesiology.

[37]  T. Fuchs-Buder,et al.  [Monitoring of neuromuscular block and prevention of residual paralysis]. , 2009, Annales francaises d'anesthesie et de reanimation.

[38]  B. Sweeney,et al.  Recovery from neuromuscular blockade: a survey of practice. , 2006, Anaesthesia.

[39]  J. Hunter,et al.  The doughnut and the hole: a new pharmacological concept for anaesthetists. , 2006, British journal of anaesthesia.

[40]  M. Avidan,et al.  Impact of anesthesia management characteristics on severe morbidity and mortality: are we convinced? , 2006, Anesthesiology.

[41]  C. Baillard,et al.  Postoperative residual neuromuscular block: a survey of management. , 2005, British journal of anaesthesia.

[42]  M. Warner.  Impact of Anesthesia Management Characteristics on Severe Morbidity and Mortality: Are We Convinced? , 2005 .

[43]  B. Plaud,et al.  Residual Paralysis in the PACU after a Single Intubating Dose of Nondepolarizing Muscle Relaxant with an Intermediate Duration of Action , 2003, Anesthesiology.

[44]  J. Salmerón,et al.  Preferences of Mexican anesthesiologists for vecuronium, rocuronium, or other neuromuscular blocking agents: a survey , 2002, BMC anesthesiology.

[45]  A. Bom,et al.  Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. , 2002, Journal of medicinal chemistry.

[46]  J. Mitchell.  Recommendations for standards of monitoring during anaesthesia and recovery , 2001, Anaesthesia.

[47]  C. Baillard,et al.  Residual curarization in the recovery room after vecuronium. , 2000, British journal of anaesthesia.

[48]  P. White,et al.  Reversal of neuromuscular blockade. , 1998, Anesthesia and analgesia.

[49]  H. Mowafi,et al.  Dose-response relationships for neostigmine antagonism of rocuronium-induced neuromuscular block in children and adults. , 1996, British journal of anaesthesia.

[50]  J. Hunter.  Is it always necessary to antagonize residual neuromuscular block? Do children differ from adults? , 1996, British journal of anaesthesia.

[51]  O. Meretoja,et al.  Reversal of atracurium‐induced neuromuscular block in paediatric patients , 1995, Acta anaesthesiologica Scandinavica.

[52]  J. Caldwell.  Reversal of Residual Neuromuscular Block with Neostigmine at One to Four Hours After a Single Intubating Dose of Vecuronium , 1995, Anesthesia and analgesia.

[53]  P. White,et al.  Effect of Antagonism of Mivacurium-Induced Neuromuscular Block on Postoperative Emesis in Children , 1995, Anesthesia and analgesia.

[54]  D. Bevan,et al.  Reversal of doxacurium and pancuronium neuromuscular blockade with neostigmine in children , 1994, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[55]  G. Meakin,et al.  Antagonism of intense atracurium-induced neuromuscular block in children. , 1991, British journal of anaesthesia.

[56]  R. Miller,et al.  The Neuromuscular Pharmacology of Neostigmine in Infants and Children , 1983, Anesthesiology.